Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor

Long-term avelumab in advanced non-small-cell lung cancer: Summaries and post hoc analyses from JAVELIN Solid Tumor

Background: This study examined patients with advanced non-small-cell lung cancer who received long-term avelumab (anti-PD-L1) in a large phase Ib trial (JAVELIN Solid Tumor). Methods: Patients receiving >2 years of avelumab were reviewed and exploratory descriptive analyses were conducted. Resul...

Full description

Bibliographic Details
Main Authors: Bajars, M. (Author), Bennouna, J. (Author), Goel, S. (Author), Gulley, J.L (Author), Hrinczenko, B. (Author), Iannotti, N. (Author), Kelly, K. (Author), Manitz, J. (Author), Ruisi, M. (Author), Safran, H. (Author), Spigel, D. (Author), Taylor, M.H (Author), Verschraegen, C. (Author), Wong, D.J (Author)
Format: Article
Language:English
Published: Future Medicine Ltd. 2022
Subjects:
Antibodies, Monoclonal, Humanized
avelumab
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
Clinical trials
disease exacerbation
Disease Progression
human
Humans
Immunotherapy
Lung
Lung Neoplasms
lung tumor
Metastasis
monoclonal antibody
non small cell lung cancer
pathology
programmed death 1 ligand 1
Solid tumors
Online Access:View Fulltext in Publisher

Similar Items

Similar Items